CM 313
Alternative Names: CM-313Latest Information Update: 25 Jun 2024
At a glance
- Originator KeyMed Biosciences
- Developer Institute of Hematology & Blood Diseases Hospital; KeyMed Biosciences
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; Phagocyte stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Idiopathic thrombocytopenic purpura
- Phase I/II Systemic lupus erythematosus
- No development reported Lymphoma; Multiple myeloma
Most Recent Events
- 20 Jun 2024 Efficacy and adverse events data from a phase II trial in Idiopathic thrombocytopenic purpura released by KeyMed Biosciences
- 28 May 2024 No recent reports of development identified for phase-I development in Lymphoma in China (IV, Infusion)
- 28 May 2024 No recent reports of development identified for phase-I development in Multiple-myeloma(Combination therapy, First-line therapy) in China (IV, Infusion)